SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to mixed reactions following earnings, with debates over its high P/E ratio and valuation despite revenue beats and raised guidance; Michael Burry's reported short position is fueling bearish sentiment. The community is split, with bulls citing strong growth and AI platform adoption, while bears express concerns about overvaluation and reliance on government contracts.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is trending as community members express strong bullish sentiment and promote its association with the Solana ecosystem. There is active discussion around community building, long-term vision, and dismissing negative sentiment. The community emphasizes resilience and supporting fellow builders in the crypto space.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is seeing increased discussion around a potential market correction, with community members pointing to AI overvaluation and heavy leveraging as potential catalysts for a significant pullback. Traders are actively debating whether this dip is a buying opportunity or the start of a longer-term bearish trend, as they watch key support levels. The conversation also includes concerns about political and economic factors influencing market direction.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is gaining traction, trending as a top crypto, with community members highlighting staking options and a strong, active team. Bullish sentiment is fueled by the project's IRL events, pro athlete sponsorships, and consistent presence on multiple platforms. Discussions also revolve around the supportive community and the potential for significant growth.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions around its recent earnings report and the outcome of a confirmatory trial for PMO therapies, with the community debating the significance of the results and potential impact on the company's future revenues. Despite an earnings beat, the stock price reaction has sparked conversations about potential market overreactions and strategic management decisions. Some investors believe the current valuation presents a buying opportunity, while others express concerns about the FDA's regulatory landscape and the long-term prospects of the company.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid discussions of market pullbacks and potential buying opportunities, with community members debating whether current levels represent a dip or further downside. Despite some bearish sentiment and concerns about institutional influence, there remains strong support for Solana's underlying technology and future potential, with some projecting ambitious price targets.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the market navigates a mixed sentiment driven by AI optimism versus concerns about valuations and economic uncertainty. Community members are actively discussing potential overextension in tech, particularly regarding names like NVDA and PLTR, while also monitoring signals for a possible market correction. News regarding potential impacts from the government shutdown and developments in U.S.-China trade relations are adding to the complex market outlook.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending downwards, fueled by broader crypto market concerns and Ethereum's recent price volatility. Community discussions revolve around whether the dip represents a buying opportunity or signals a deeper correction, with some questioning Tom Lee's influence and the company's strategy amidst market uncertainty.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

ICP is trending amid discussions about its technology and potential, with some community members highlighting its unique architecture. Increased trading volume and recent integrations are fueling bullish sentiment, while others express skepticism based on its historical price performance. Debate continues around its long-term viability and disruptive potential in the decentralized web space.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin $CAW, also known as crow with knife, is trending as community members express bullish sentiment and encourage others to "buy the dip." Community chatter highlights the token's deflationary nature, multichain functionality, and staking opportunities. Bullish investors see the token as a meme with growing utility.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for

electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy?

Madrigal (MDGL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?

Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU

MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates

Madrigal (MDGL) delivered earnings and revenue surprises of +45.40% and +32.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights

Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?

Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

​Short interest in Madrigal Pharmaceuticals rose to a four-month high, Ortex data showed, as bearish positions increased despite recent signs of stabilization in the stock following a multi-session decline.Madrigal’s stock closed at $294.64 on Friday, down $4.93 or 1.65%Short interest as a percentage of free float climbed to 38.9% from 34.8%, marking the highest level since early January,&nbsp;as per a report on The Fly. The days-to-cover ratio edged lower by 30 basis points to 6.7.The increase came as Madrigal shares found some support over the past two trading sessions, following four consecutive days of losses. The stock is down 6.1% year-to-date.The build in short positions follows Madrigal’s first-quarter earnings report last week. The company reported a net loss of $3.32 per share, narrower than analysts’ expectations for a $3.79 loss.&nbsp;Revenue for the quarter came in at $137.25 million, above the $114.19 million consensus estimate.CEO Bill Sibold said the company has delivered Rezdiffra to more than 17,000 patients since its approval as the first FDA-approved treatment for MASH, a progressive liver disease associated with metabolic dysfunction.&nbsp;He added that providers have reported improvements in liver stiffness, fat, enzymes, LDL, and triglyceride levels.On Saturday, Madrigal announced two-year results from the open-label compensated MASH cirrhosis arm of its Phase 3 MAESTRO-NAFLD-1 trial.&nbsp;Patients treated with Rezdiffra showed statistically significant improvements in liver stiffness, fat, fibrosis biomarkers, liver volume, and clinically significant portal hypertension (CSPH) risk scores.Among patients with CSPH at baseline, 65% moved into lower-risk categories by year two. Of those with probable CSPH, 57% moved to the no/low-risk category, while 14% progressed to confirmed CSPH.&nbsp;The safety profile remained consistent with previous studies. Rezdiffra was well-tolerated, with a low rate of discontinuation due to adverse events.&nbsp;The most common side effects were diarrhea, COVID-19, and nausea. Two deaths occurred during the study but were not attributed to the drug.On Stocktwits, sentiment was 'bullish' amid ‘high’ message volume.One user anticipated a rise in Madrigal stock on Monday, expressing confidence in the stock's upward momentum.&nbsp;<stembedurl>https://stocktwits.com/Wallst45/message/614200620</stembedurl>Another user echoed a similar sentiment, highlighting the potential demand for Rezdiffra, suggesting that both patients with MASH and healthcare providers would likely favor the treatment due to its lack of side effects.<stembedurl>https://stocktwits.com/BrenFal0919/message/614192080</stembedurl>The stock has declined 6.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Madrigal Pharmaceuticals logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock

Despite soaring short interest, retail sentiment remains bullish, with investors optimistic about the company’s positive trial results and the continued demand for its FDA-approved treatment, Rezdiffra.

Equity

Companies developing therapies for metabolic steatohepatitis (MASH) saw strong gains even as Novo Nordisk (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) announced that its GLP-1 drug, semaglutide, demonstrated “superior improvement” in treating the liver disease in its phase 3 ESSENCE trial.&nbsp;Shares of Madrigal Pharmaceuticals (<a class="mention" data-mention="$MDGL" data-symbol-id="MDGL" href="https://stocktwits.com/symbol/MDGL" target="_blank">$MDGL</a>), which received FDA approval earlier this year for its MASH drug, Rezdiffra, rose by 18% following the announcement, with 89Bio (<a class="mention" data-mention="$ETNB" data-symbol-id="ETNB" href="https://stocktwits.com/symbol/ETNB" target="_blank">$ETNB</a>) and Akero Therapeutics (<a class="mention" data-mention="$AKRO" data-symbol-id="AKRO" href="https://stocktwits.com/symbol/AKRO" target="_blank">$AKRO</a>) seeing gains of 15% and 4%, respectively.Novo Nordisk’s ESSENCE trial, a 240-week, double-blind study involving 1,200 adults with MASH and moderate to advanced liver fibrosis, achieved its primary endpoints.&nbsp;After 72 weeks, patients receiving a weekly dose of 2.4 mg semaglutide showed significant liver fibrosis improvement without worsening steatohepatitis, as well as steatohepatitis resolution with no worsening of liver fibrosis, compared to those on placebo.&nbsp;"We are very pleased about the ESSENCE clinical trial results and the potential of semaglutide to help people living with MASH. Among people with overweight or obesity, one in three live with MASH. This has a serious impact on their health and represents a significant unmet need," said Martin Holst Lange, Novo’s executive vice president.The FDA has yet to approve GLP-1 drugs for MASH, though several early trials have shown promise in reversing the disease’s initial stages.&nbsp;In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.&nbsp;On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.&nbsp;Canaccord boosted its target on Madrigal to $394, citing confidence in continued revenue growth, while UBS increased its target to $441, highlighting an “underappreciated opportunity” in MASH and potential validation from Novo’s findings.<figure class="image"><a href="https://stocktwits.com/symbol/MDGL"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/MDGL_sentiment_and_message_volume_Nov_1_69ab9366a3.png" alt="MDGL sentiment and message volume Nov 1.png" width="1314" height="320"></a><figcaption>MDGL sentiment and message volume Nov 1 as of 1:30 pm ET | source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment for MDGL remained ‘extremely bullish’ as of Friday afternoon amid a spike in message volume, with many fixated on Thursday’s strong results.<stembedurl>https://stocktwits.com/GXD_Texas/message/590911195</stembedurl>Some were also penciling in the next resistance levels for the stock that broke out over $300 this week.<stembedurl>https://stocktwits.com/TheProphetOfProfit/message/590910821</stembedurl>Madrigal’s stock has surged over 33% year-to-date, significantly outperforming broader market benchmarks.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next: <a href="https://stocktwits.com/news-articles/markets/equity/epix-stock-falls-after-drug-trial-fails/cJEYt4ERBm">Essa Pharma Stock Crashes After Lead Drug Candidate Trial Flops: Retail Hopes Fade</a>

On Thursday, Madrigal reported robust quarterly earnings, driven by Rezdiffra sales, which led to raised price targets and positive analyst notes.

Madrigal Pharma Stock Soars Despite Novo Nordisk’s ‘Superior’ MASH Trial Results: Retail Bullish On Earnings Beat

In March, Madrigal’s Rezdiffra became the first FDA-approved treatment for MASH with moderate to advanced liver scarring.

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.

Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word...

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MDGL
Madrigal Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MDGL News

MDGLMadrigal Pharmaceuticals Inc